Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights. The FDA submission is ...

Easily to use: Mint apps easy to use interface helps you find all the relevant information within few clicks, be it latest financial news or senxes updates. Its easily available on right on the home ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...